EV Biologics, Inc. (YECO)
USD 0.09
(-0.12%)
USD 0.09
(-0.12%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 48.9 Thousand USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 118.9 Thousand USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | 1.53 Million USD | -90.66% |
| 2016 | 16.47 Million USD | -2.3% |
| 2015 | 16.86 Million USD | -0.5% |
| 2014 | 16.95 Million USD | 8.0% |
| 2013 | 15.69 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 138.01 Thousand USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2024 Q1 | - USD | -100.0% |
| 2023 FY | 48.9 Thousand USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q4 | 48.9 Thousand USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 FY | - USD | -100.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2021 Q2 | 118.9 Thousand USD | 0.0% |
| 2021 FY | 118.9 Thousand USD | 0.0% |
| 2021 Q3 | 118.9 Thousand USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2017 FY | 1.53 Million USD | -90.66% |
| 2017 Q4 | 16.9 Million USD | 0.0% |
| 2017 Q2 | 345.86 Thousand USD | 0.0% |
| 2017 Q1 | 345.86 Thousand USD | 18.07% |
| 2016 FY | 16.47 Million USD | -2.3% |
| 2016 Q4 | 292.93 Thousand USD | -67.85% |
| 2016 Q3 | 911.22 Thousand USD | -52.85% |
| 2016 Q2 | 1.93 Million USD | -55.16% |
| 2016 Q1 | 4.31 Million USD | -10.0% |
| 2015 Q1 | 3.95 Million USD | -4.55% |
| 2015 Q4 | 4.78 Million USD | -12.05% |
| 2015 Q3 | 5.44 Million USD | 17.71% |
| 2015 FY | 16.86 Million USD | -0.5% |
| 2015 Q2 | 4.62 Million USD | 16.85% |
| 2014 Q4 | 4.14 Million USD | 0.36% |
| 2014 Q1 | 4.15 Million USD | 1.55% |
| 2014 Q2 | 4.57 Million USD | 10.11% |
| 2014 Q3 | 4.13 Million USD | -9.69% |
| 2014 FY | 16.95 Million USD | 8.0% |
| 2013 Q2 | 3.79 Million USD | 8.36% |
| 2013 Q1 | 3.5 Million USD | -16.46% |
| 2013 Q3 | 4.12 Million USD | 8.62% |
| 2013 FY | 15.69 Million USD | 0.0% |
| 2013 Q4 | 4.09 Million USD | -0.8% |
| 2012 Q4 | 4.19 Million USD | 99900.0% |
| 2012 Q3 | 4196.30 USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 2104.92% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.582% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 115.305% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.959% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.19% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 201.328% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 139.356% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.674% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -1476.402% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.501% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 25.602% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 243.192% |
| Mesoblast Limited | -35.16 Million USD | 100.139% |
| Marizyme, Inc. | 457.7 Thousand USD | 89.316% |
| Genus plc | 178.7 Million USD | 99.973% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.978% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 21.415% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 88.078% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 544.545% |
| ContraFect Corporation | -154 Thousand USD | 131.753% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 197.8% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 36.296% |
| IMV Inc. | -962.29 Thousand USD | 105.082% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 112.619% |
| MultiCell Technologies, Inc. | 49.32 USD | -99048.418% |
| ONE Bio Corp. | 20.12 Million USD | 99.757% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.879% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | -8988.00 USD | 644.059% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.827% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 417.038% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.89% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 104.284% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 30.143% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 1087.48% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 65.196% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 150.146% |
| GB Sciences, Inc. | -624.00 USD | 7936.538% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 156.842% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 23609.615% |
| Enzolytics Inc. | 30.7 Thousand USD | -59.242% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 89.864% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.996% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 109.504% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 92.079% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.988% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 652.168% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 158.319% |
| Kadimastem Ltd | -630.13 Thousand USD | 107.76% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 95.051% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.491% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.683% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 513.181% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 72.304% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 72.304% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 96.397% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 268.621% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 89.134% |
| SYBLEU INC | 11.69 Thousand USD | -318.092% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 98.939% |
| Bioxytran, Inc. | -8285.00 USD | 690.223% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 113.11% |
| Neutra Corp. | 14.33 Thousand USD | -241.123% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 159.634% |
| PureTech Health plc | -1.6 Million USD | 103.051% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 104.884% |
| IXICO plc | 3.27 Million USD | 98.505% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 107.046% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 102.73% |
| CSL Limited | 7.7 Billion USD | 99.999% |
| Cellectis S.A. | 18 Thousand USD | -171.667% |